LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Mutations of the LRRK2 gene that encodes the protein dardarin occur in Parkinson disease (PD)1 with the G2019S change being the most common cause of hereditary parkinsonism. While the G2019S mutation phenotype is that of typical PD,2 three different amino acid substitutions at residue 1441 (4322G>A: [R1441H], 4321C>T: [R1441C], 4321C>G: [R1441G]) have been associated with pleomorphic phenotypic expressions.3 There is evidence, however, that not all LRRK2 mutations are sufficient to cause PD and that additional genetic or environmental factors may be involved. An oligogenic inheritance for PD has also been suggested in a study of 247 index patients with PD from Crete.4 Here we searched for susceptibility genes to PD in our cohort of 266 cases with PD and 13 patients with progressive supranuclear palsy (PSP) by testing them for LRRK2 mutations.
Methods.
PD was diagnosed by established criteria.4 PSP was diagnosed by the National Institute of Neurologic Disorders and Stroke–SPSP criteria, requiring early postural instability and falls, vertical supranuclear palsy, pseudobulbar palsy, and akinetic-rigid parkinsonism (with prominent axial rigidity) unrelieved by levodopa. Controls (n = 300) were healthy subjects natives of Crete. All patients and controls were analyzed for five LRRK2 …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutationsA. S. Chen-Plotkin, W. Yuan, C. Anderson et al.Neurology, October 03, 2007 -
Article
The scientific and clinical basis for the treatment of Parkinson disease (2009)C. Warren Olanow, Matthew B. Stern, Kapil Sethi et al.Neurology, May 26, 2009 -
Articles
LRRK2 gene in Parkinson diseaseMutation analysis and case control association studyC. Paisán-Ruíz, A. E. Lang, T. Kawarai et al.Neurology, June 15, 2005 -
Clinical/Scientific Notes
Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorderRubén Fernández-Santiago, Alex Iranzo, Carles Gaig et al.Neurology, January 08, 2016